other material
confidence high
sentiment positive
materiality 0.65
Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis
Aurinia Pharmaceuticals Inc.
- Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.
- Activity scores improved similarly in both arms; chronicity scores stable.
- Data differentiates LUPKYNIS from first-generation CNIs on nephrotoxicity.
- Further data to be presented at Congress of Clinical Rheumatology May 4-7, 2023.
- Conference call/webcast at 8:30 am EDT on April 5, 2023.